These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20035387)

  • 21. Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma?
    Krishnan A; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e445-e446. PubMed ID: 32470436
    [No Abstract]   [Full Text] [Related]  

  • 22. Evolving paradigms in the treatment of newly diagnosed multiple myeloma.
    Larocca A; Palumbo A
    J Natl Compr Canc Netw; 2011 Oct; 9(10):1186-96. PubMed ID: 21975915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
    Mikhael JR; Dingli D; Roy V; Reeder CB; Buadi FK; Hayman SR; Dispenzieri A; Fonseca R; Sher T; Kyle RA; Lin Y; Russell SJ; Kumar S; Bergsagel PL; Zeldenrust SR; Leung N; Drake MT; Kapoor P; Ansell SM; Witzig TE; Lust JA; Dalton RJ; Gertz MA; Stewart AK; Rajkumar SV; Chanan-Khan A; Lacy MQ;
    Mayo Clin Proc; 2013 Apr; 88(4):360-76. PubMed ID: 23541011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current management and emerging treatment strategies for multiple myeloma.
    Lei M; Kim EB; Branagan A; Lou U; Zemel M; Raje N
    Rinsho Ketsueki; 2019; 60(9):1243-1256. PubMed ID: 31597850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma.
    Patriarca F; Sperotto A; Filì C; Zaja F; Prosdocimo S; Fanin R
    Haematologica; 2002 Jul; 87(7):779-81. PubMed ID: 12091134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
    Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
    Guglielmelli T; Palumbo A
    Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.
    Laubach J; Garderet L; Mahindra A; Gahrton G; Caers J; Sezer O; Voorhees P; Leleu X; Johnsen HE; Streetly M; Jurczyszyn A; Ludwig H; Mellqvist UH; Chng WJ; Pilarski L; Einsele H; Hou J; Turesson I; Zamagni E; Chim CS; Mazumder A; Westin J; Lu J; Reiman T; Kristinsson S; Joshua D; Roussel M; O'Gorman P; Terpos E; McCarthy P; Dimopoulos M; Moreau P; Orlowski RZ; Miguel JS; Anderson KC; Palumbo A; Kumar S; Rajkumar V; Durie B; Richardson PG
    Leukemia; 2016 May; 30(5):1005-17. PubMed ID: 26710887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing.
    Tariman JD; Estrella SM
    Oncol Nurs Forum; 2005 Nov; 32(6):E127-38. PubMed ID: 16270103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of high-risk Myeloma: an evidence-based review of treatment strategies.
    Lehners N; Hayden PJ; Goldschmidt H; Raab MS
    Expert Rev Hematol; 2016 Aug; 9(8):753-65. PubMed ID: 27337562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
    Kumar SK; Mikhael JR; Buadi FK; Dingli D; Dispenzieri A; Fonseca R; Gertz MA; Greipp PR; Hayman SR; Kyle RA; Lacy MQ; Lust JA; Reeder CB; Roy V; Russell SJ; Short KE; Stewart AK; Witzig TE; Zeldenrust SR; Dalton RJ; Rajkumar SV; Bergsagel PL
    Mayo Clin Proc; 2009 Dec; 84(12):1095-110. PubMed ID: 19955246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)].
    Lokhorst H; Huijgens PC; Raymakers R; Bos GM; Vellenga E; Wijermans PW; Sonneveld P;
    Ned Tijdschr Geneeskd; 2005 Apr; 149(15):808-13. PubMed ID: 15850271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
    Siegel DS; Vij R; Jakubowiak AJ
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
    Palumbo A; Sezer O; Kyle R; Miguel JS; Orlowski RZ; Moreau P; Niesvizky R; Morgan G; Comenzo R; Sonneveld P; Kumar S; Hajek R; Giralt S; Bringhen S; Anderson KC; Richardson PG; Cavo M; Davies F; Bladé J; Einsele H; Dimopoulos MA; Spencer A; Dispenzieri A; Reiman T; Shimizu K; Lee JH; Attal M; Boccadoro M; Mateos M; Chen W; Ludwig H; Joshua D; Chim J; Hungria V; Turesson I; Durie BG; Lonial S;
    Leukemia; 2009 Oct; 23(10):1716-30. PubMed ID: 19494840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple Myeloma: Diagnosis and Treatment.
    Rajkumar SV; Kumar S
    Mayo Clin Proc; 2016 Jan; 91(1):101-19. PubMed ID: 26763514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
    Merz M; Neben K; Raab MS; Sauer S; Egerer G; Hundemer M; Hose D; Kunz C; Heiß C; Ho AD; Goldschmidt H; Hillengass J
    Ann Oncol; 2014 Jan; 25(1):189-95. PubMed ID: 24356629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.